# TMEM209

## Overview
TMEM209 is a gene that encodes the transmembrane protein 209, which is categorized as a transmembrane protein. This protein plays a significant role in various cellular processes, particularly in the context of cancer biology. TMEM209 is involved in the regulation of protein stability and signaling pathways, notably the Wnt/β-catenin pathway, which is crucial for cell proliferation and metastasis. The protein's interaction with Karyopherin-β1 (KPNB1) highlights its importance in the progression of hepatocellular carcinoma (HCC) by preventing the degradation of KPNB1 and facilitating the nuclear translocation of β-catenin (Fang2024TMEM209). Beyond its oncogenic roles, TMEM209 has been implicated in other diseases, including esophageal squamous cell carcinoma and clonal hematopoiesis, and is being explored as a potential therapeutic target (Zhang2024Risk; Kar2022Genomewide).

## Clinical Significance
TMEM209 has been implicated in several diseases due to its role in cellular processes and signaling pathways. In hepatocellular carcinoma (HCC), TMEM209 is upregulated and acts as an oncogene by promoting cancer progression through the activation of the Wnt/β-catenin signaling pathway. This activation is facilitated by the stabilization of KPNB1, which enhances the nuclear translocation of β-catenin, leading to increased cell proliferation and metastasis. High expression levels of TMEM209 in HCC are associated with poor prognosis, affecting overall survival and disease-free survival (Fang2024TMEM209).

In esophageal squamous cell carcinoma (ESCC), TMEM209 is also upregulated and linked to tumor progression. It is associated with the tumor microenvironment and immune cell infiltration, suggesting its potential as a prognostic factor and therapeutic target in ESCC (Zhang2024Risk).

Additionally, TMEM209 has been identified in a genome-wide association study as a locus associated with clonal hematopoiesis, particularly in relation to TET2 mutations, indicating a potential role in hematological conditions (Kar2022Genomewide). Rare genetic variants in TMEM209 have also been found in families with Parkinson's disease, suggesting a possible contribution to neurological disorders (Aslam2021Putative).

## Interactions
TMEM209 interacts with Karyopherin-β1 (KPNB1), a protein involved in nuclear import processes. This interaction is crucial for the progression of hepatocellular carcinoma (HCC) as it stabilizes KPNB1 by inhibiting its ubiquitination and subsequent degradation. TMEM209 achieves this by competitively inhibiting the binding of KPNB1 to the E3 ubiquitin ligase RCHY1, preventing KPNB1's ubiquitination. This stabilization of KPNB1 enhances the nuclear translocation of β-catenin, thereby activating the Wnt/β-catenin signaling pathway, which is associated with increased cell proliferation and metastasis in HCC (Fang2024TMEM209).

The interaction between TMEM209 and KPNB1 was confirmed through coimmunoprecipitation (Co-IP) assays and GST-pull-down experiments, which identified that the interaction primarily involves the 1-211 residues of KPNB1. This interaction does not affect KPNB1 mRNA levels, indicating that TMEM209 regulates KPNB1 at the protein level (Fang2024TMEM209). The role of TMEM209 in stabilizing KPNB1 and activating the Wnt/β-catenin pathway highlights its potential as a therapeutic target in HCC (Fang2024TMEM209).


## References


[1. (Aslam2021Putative) Muhammad Aslam, Nirosiya Kandasamy, Anwar Ullah, Nagarajan Paramasivam, Mehmet Ali Öztürk, Saima Naureen, Abida Arshad, Mazhar Badshah, Kafaitullah Khan, Muhammad Wajid, Rashda Abbasi, Muhammad Ilyas, Roland Eils, Matthias Schlesner, Rebecca C. Wade, Nafees Ahmad, and Jakob von Engelhardt. Putative second hit rare genetic variants in families with seemingly gba-associated parkinson’s disease. npj Genomic Medicine, January 2021. URL: http://dx.doi.org/10.1038/s41525-020-00163-8, doi:10.1038/s41525-020-00163-8. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41525-020-00163-8)

[2. (Fang2024TMEM209) Haoran Fang, Xiaoyi Shi, Jie Gao, Zhiping Yan, Yun Wang, Yabin Chen, Jiacheng Zhang, and Wenzhi Guo. Tmem209 promotes hepatocellular carcinoma progression by activating the wnt/β-catenin signaling pathway through kpnb1 stabilization. Cell Death Discovery, October 2024. URL: http://dx.doi.org/10.1038/s41420-024-02207-9, doi:10.1038/s41420-024-02207-9. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41420-024-02207-9)

[3. (Zhang2024Risk) Xun Zhang, Chuting Yu, Siwei Zhou, Yanhui Zhang, Bo Tian, Yan Bian, Wei Wang, Han Lin, and Luo-Wei Wang. Risk model based on genes regulating the response of tumor cells to t-cell-mediated killing in esophageal squamous cell carcinoma. Aging, February 2024. URL: http://dx.doi.org/10.18632/aging.205495, doi:10.18632/aging.205495. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.18632/aging.205495)

[4. (Kar2022Genomewide) Siddhartha P. Kar, Pedro M. Quiros, Muxin Gu, Tao Jiang, Jonathan Mitchell, Ryan Langdon, Vivek Iyer, Clea Barcena, M. S. Vijayabaskar, Margarete A. Fabre, Paul Carter, Slavé Petrovski, Stephen Burgess, and George S. Vassiliou. Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis. Nature Genetics, 54(8):1155–1166, July 2022. URL: http://dx.doi.org/10.1038/s41588-022-01121-z, doi:10.1038/s41588-022-01121-z. This article has 147 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41588-022-01121-z)